Overview

Evaluate Safety, Efficacy and Pharmacokinetics

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of the study is to demonstrate equivalent pharmacokinetics (PK)
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Celltrion
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Trastuzumab
Criteria
Inclusion Criteria:

- Are females

- Have a Her 2 over-expression

- Have ECOG 0 or 1

Exclusion Criteria:

- Current clinical or radiographic evidence CNS metastases

- Current Known infection

- Pregnant or nursing mother